Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (191-200 of 271) with videos related to

Pageof 28
Sort By:
Genome Research|October 26, 2013
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defectsJeremy M Simon, Kathryn E Hacker, Darshan Singh, et al.
The Lancet. Oncology|September 22, 2018
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trialEric Jonasch, Ian E McCutcheon, Dan S Gombos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell CarcinomaXian-De Liu, Yan-Ting Zhang, Daniel J McGrail, et al.
The Lancet. Oncology|October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, et al.
International Journal of Molecular Sciences|March 6, 2021
Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian PatientsFlávia Gonçalves Fernandes, Henrique Cesar Santejo Silveira, João Neif Antonio Júnior, et al.
European Urology|December 3, 2015
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 TrialNizar M Tannir, Eric Jonasch, Laurence Albiges, et al.
Journal of Cellular Biochemistry|July 20, 2004
Lysophosphatidic acid production and action: validated targets in cancer?Makiko Umezu-Goto, Janos Tanyi, John Lahad, et al.
The Oncologist|November 30, 2023
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint TherapyAndrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, et al.
European Urology|February 21, 2016
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic AlterationsGabriel G Malouf, Siraj M Ali, Kai Wang, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomasKanishka Sircar, Suk-Young Yoo, Tadeusz Majewski, et al.
Pageof 28

Showing results (191-200 of 271) with videos related to

Sort By:
Pageof 28
Genome Research|October 26, 2013
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defectsJeremy M Simon, Kathryn E Hacker, Darshan Singh, et al.
The Lancet. Oncology|September 22, 2018
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trialEric Jonasch, Ian E McCutcheon, Dan S Gombos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell CarcinomaXian-De Liu, Yan-Ting Zhang, Daniel J McGrail, et al.
The Lancet. Oncology|October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, et al.
International Journal of Molecular Sciences|March 6, 2021
Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian PatientsFlávia Gonçalves Fernandes, Henrique Cesar Santejo Silveira, João Neif Antonio Júnior, et al.
European Urology|December 3, 2015
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 TrialNizar M Tannir, Eric Jonasch, Laurence Albiges, et al.
Journal of Cellular Biochemistry|July 20, 2004
Lysophosphatidic acid production and action: validated targets in cancer?Makiko Umezu-Goto, Janos Tanyi, John Lahad, et al.
The Oncologist|November 30, 2023
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint TherapyAndrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, et al.
European Urology|February 21, 2016
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic AlterationsGabriel G Malouf, Siraj M Ali, Kai Wang, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomasKanishka Sircar, Suk-Young Yoo, Tadeusz Majewski, et al.
Pageof 28